NASDAQ:PSTV Plus Therapeutics Q4 2025 Earnings Report $1.78 -0.09 (-4.81%) As of 10/1/2026 ProfileEarnings HistoryForecast Plus Therapeutics EPS ResultsActual EPS$6.25Consensus EPS -$0.03Beat/MissBeat by +$6.28One Year Ago EPSN/APlus Therapeutics Revenue ResultsActual Revenue$1.37 millionExpected Revenue$1.23 millionBeat/MissBeat by +$139.00 thousandYoY Revenue GrowthN/APlus Therapeutics Announcement DetailsQuarterQ4 2025Date3/12/2026TimeBefore Market OpensConference Call DateThursday, March 12, 2026Conference Call Time7:00AM ETConference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) Plus Therapeutics Earnings HeadlinesPlus Therapeutics’ CNSide Begins Billing as Test Volumes SurgeOctober 1 at 5:02 AM | americanbankingnews.comPlus Therapeutics, Inc. (NASDAQ:PSTV) Given Average Rating of "Hold" by BrokeragesSeptember 22, 2026 | americanbankingnews.comThe only 5 stocks that matterSpaceX's IPO reportedly minted 4,400 new millionaires, and OpenAI is said to be eyeing a 1 trillion dollar IPO as soon as this fall. TradeSmith CEO Keith Kaplan says chasing the next hot IPO isn't necessary. His AI-driven system, built on a platform pioneered by Google, ranks every stock in the S&P 500 and narrows the list to just five names to hold each month. Backtests show the Top Five Stocks outperformed the S&P 500 by 4x in August alone.October 2 at 1:00 AM | TradeSmith (Ad)Cerenome Announces Up to $20 Million Financing Facility with Royalty-Based RepaymentSeptember 10, 2026 | globenewswire.comCerenome Highlights Presentations at the 2026 SNO/ASCO CNS Metastases Conference Demonstrating Progress in Both Therapeutics and Diagnostics Business LinesAugust 20, 2026 | globenewswire.comCerenome Reports Second Quarter 2026 Financial Results and Business UpdateAugust 14, 2026 | globenewswire.comSee More Plus Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Plus Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Plus Therapeutics and other key companies, straight to your email. Email Address About Plus TherapeuticsPlus Therapeutics (NASDAQ:PSTV) is a clinical-stage pharmaceutical company focused on developing targeted radiotherapeutics for difficult-to-treat cancers. The company’s technology is designed to deliver radioactive agents directly to tumors while limiting exposure to surrounding healthy tissue. Its lead investigational product is rhenium-186 nanoliposome, also known as 186RNL or RNL. The treatment uses nanoliposomes to encapsulate the radioisotope rhenium-186 and is being evaluated for cancers affecting the central nervous system, including recurrent glioblastoma and leptomeningeal metastases. Plus Therapeutics is also studying potential applications in other solid tumors. Plus Therapeutics is headquartered in Austin, Texas, and conducts its development activities through collaborations with clinical and research institutions. The company was formerly known as Cytori Therapeutics before adopting the Plus Therapeutics name. Marc H. Hedrick serves as president and chief executive officer.View Plus Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles McCormick Stock Trades Cheap, Offers Dividend Growth and Unilever Deal UpsideMicron’s Earnings Reveal Why the AI Memory Boom May Last LongerAnthropic's IPO Could Put Amazon's and Alphabet's Paper Profits to the TestBoeing’s Fighter Victory Opens the Door to Decades of Defense RevenueCorning and AT&T's $3 Billion Fiber Deal Reveals Where AI Spending Goes NextTarget's Holiday Blitz: Slashing Prices to Capture Market ShareCleared for Takeoff: AAR Corp. Expands Its Aerospace Aftermarket Reach Upcoming Earnings PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
